Palo Alto CA, USA: 12 October 2018 – Varian (NYSE: VAR) today announced the acquisition of privately-held software company Noona Healthcare, developer of a cloud-based, mobile service designed to capture cancer patient-reported outcomes (PROs). The Noona patient software app lets clinics capture PROs and communicate directly with patients. This acquisition expands Varian’s portfolio of cancer care solutions and fits the company’s long-term growth and value creation strategy.

Noona’s intuitive user interface creates an engaging experience for patients that encourages a high rate of adoption and adherence over long periods. Noona helps patients and care teams to proactively manage patient symptoms, which could lead to improved clinical outcomes and reduced hospitalization and emergency room visits.

As part of a succession plan, Gimv is investing in the two German companies Medi-Markt Homecare-Service GmbH and Medi Markt Service Nord Ost GmbH as well as a number of affiliated companies. These two leading service providers in incontinence care will continue to grow in the coming years as a newly formed group with the support of Gimv.

Antwerp / Munich / Mannheim / Isenbüttel, 18 October 2018, 07:30 am – European investment company Gimv has reached an agreement on the takeover of the majority of both Medi-Markt Homecare-Service GmbH based in Mannheim as well as Isenbüttel-based Medi Markt Service Nord Ost GmbH. These transactions are part of a succession plan for both companies. Gimv is thus expanding its Health & Care portfolio with a leading supplier of medical supplies in Germany, which is expected to continue to grow in the coming years. The remaining shares will be acquired by the newly appointed CEO of the Medi Markt Group,Markus Reichel. The transaction is subject to customary approval requirements and is expected to close within a few weeks.

The two companies and their affiliates, which together employ around 225 people, will form one group as of this transaction and will operate jointly under the Medi-Markt brand, headquartered in Mannheim. Markus Reichel, formerly managing director of Medi-Markt Homecare-Service GmbH, will become managing director of the new group and a co-shareholder. The companies are specialised mail-order providers of homecare supplies with a particular focus on absorbing incontinence. Further product groups include revulsive incontinence, diabetes control, stoma care, enteral nutrition, disinfection and protection as well as personal hygiene, supplying a total of c.12,000 different products. The companies distribute branded and private label products. Medi-Markt is one of the major providers in the country for incontinence aids and stoma care. The group has a combined annual turnover of more than 50 million EUR.

Medi-Markt supplies around 150,000 end-consumers annually. The majority of the products are reimbursed by health insurances, for whom Medi-Markt has been a reliable partner for many years.

“Together with our new growth partner Gimv, we want to further expand our product offering and advance into adjacent segments. We are also considering acquisitions of suitable companies,” explains Markus Reichel, Managing Director of Medi-Markt Homecare-Service GmbH and future CEO of the group. The business benefits from the demographic change since Medi Markt primarily caters an ageing population: today c. 7 million people suffer from incontinence in Germany. This number is expected to further increase to nine million over the next 20 years. “Medi-Markt’s high quality products and the company’s customer-centric approach enable many people to maintain a more independent lifestyle. At the same time, due to lean organizational structures, the company improves efficiency of care,” says Philipp v. Hammerstein, Partner at Gimv in the Health & Care segment in Munich. “We are l ooking forward to continuing the success story of these two leading specialists, while leveraging further potential related to the merger. Together with the experienced management team, we will focus on organic growth as well as on buy-and-build opportunities.”

The new investment marks Gimv’s seventh acquisition in the German-speaking healthcare market. This means that Gimv currently has 20 participations in companies in the healthcare and life sciences sector. This acquisition further underpins Gimv’s position as one of the most active European investors in the healthcare industry. The portfolio also includes several clinic and practice groups, medical technology and biotech companies.

Further details about the transaction will not be published.

17 October 2018 – Montagu Private Equity (“Montagu”) and Astorg (“Astorg”) today announce that Montagu has signed an agreement to sell Nemera (“the company”), a leading global manufacturer of drug administration systems for the pharmaceutical industry, to Astorg.

While committing to acquire the business in full, Astorg has offered Montagu the opportunity to reinvest as a partner in the next phase of Nemera’s growth, alongside its management team. Given the strength and growth potential of the company, Montagu has elected to exercise this option and form an equal partnership with Astorg to support Nemera’s management team in delivering the company’s ambitious development plans. Further terms of the transaction were not disclosed.

Headquartered in La Verpillière (France), Nemera designs, develops, and manufactures a full range of drug delivery devices including auto-injectors, inhalers, insulin pens, eye droppers and pumps from four state-of-the-art manufacturing sites in France, Germany and the US. Its products are sold to a variety of blue-chip customers from the pharmaceutical, biotech and generics industries. Nemera employs 1,950 full-time-equivalent employees.

With the support of Montagu, Nemera has grown its sales by 50% and increased by 25% its workforce since its carve out from Rexam PLC in 2014. The company has also further strengthened its world-class innovation centre and developed new services in line with its long-term commitment to improve patients’ lives and remain the partner of choice for its longstanding clients.

Following the transaction, Astorg will jointly control Nemera with Montagu, providing the financial resources and sector expertise required to support management’s ambitious growth plans, both organically and via carefully selected add-on acquisitions.

Marc Haemel, Nemera’s CEO, said “We are excited about our new partnership with Astorg and Montagu. We have been very impressed by Astorg’s in-depth understanding of our business, as well as their overall expertise in the healthcare space, which will help us fulfill our growth ambitions. We are also delighted to continue working with Montagu, who has significantly contributed to our success.

This transaction opens a promising new chapter for the company. It will allow us, with the support of Astorg and the continued commitment of Montagu, to build upon the company’s strengths and accelerate the development of our proprietary device portfolio and innovation capabilities, while also exploring additional value-creating opportunities.”

Completion of the transaction is subject to satisfactory clearance from relevant anti-trust authorities.

Astorg was advised by Citigroup and Latham & Watkins. Montagu was advised by HSBC, Morgan Stanley and Weil Gotshal.

Carlyle’s Global Healthcare Network and Experience to Help Expand the Business

Hangzhou, China – Global alternative asset manager The Carlyle Group (NASDAQ: CG) today announced that it, together with Meinian Onehealth Healthcare Holdings Co., Ltd., has invested in and become the single largest shareholder of, Adicon Holding Limited, one of the largest independent clinical laboratory (ICL) companies in China. Equity for the investment came from Carlyle Asia Partners V, Carlyle’s flagship US$6.55 billion fund focused on buyout and strategic investments across a range of sectors in Asia Pacific.

Established in 2004, Adicon operates 20 fully-owned diagnostic laboratories in China, offering diagnostic testing outsourcing services to more than 10,000 active customers, including hospitals, clinics and contract research organizations (CROs) in 28 provinces. China’s ICL industry is a fast-growing market, driven by growing healthcare expenditure, rising diagnostic demand, continued technology innovation and hospital cost control trends. As an ICL industry pioneer, Adicon has developed a scalable operation with high quality standards and a network of laboratories certified with China National Accreditation Services for Conformity Assessment (CNAS). Adicon’s comprehensive test portfolio includes a range of esoteric tests, addressing diverse customer demands.

Ling Yang, Managing Director of the Carlyle Asia Buyout advisory team, said, “We are excited to have the opportunity to invest in Adicon. Adicon is a platform company, which taps into the sustained growth and innovation in China’s healthcare market and helps the health system achieve cost savings. We have seen ICL leaders grow into substantial businesses in mature markets, and believe Adicon has similar potential. We look forward to working with our partners and the existing management team to build this company together.”

The Carlyle Group has invested more than US$11.5 billion of equity in more than 65 transactions in the global healthcare industry as of June 30, 2018. In Asia, Carlyle has invested approximately US$1.5 billion in 10 healthcare companies.

As one of the first and most active international private equity investors in China, Carlyle has adopted a local approach towards investments in China for two decades. Carlyle has invested more than US$8 billion of equity in nearly 100 private equity transactions across China through its US dollar and RMB investment vehicles as of June 30, 2018.

* * * * *

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global alternative asset manager with $210 billion of assets under management across 335 investment vehicles as of June 30, 2018. Carlyle’s purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments – Corporate Private Equity, Real Assets, Global Credit and Investment Solutions – in Africa, Asia, Australia, Europe, the Middle East, North America and South America. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy, financial services, healthcare, industrial, real estate, technology & business services, telecommunications & media and transportation. The Carlyle Group employs more than 1,625 people in 31 offices across six continents.

Web: www.carlyle.com

Videos: www.youtube.com/onecarlyle

Tweets: www.twitter.com/onecarlyle

Podcasts: www.carlyle.com/about-carlyle/market-commentary

Media Contacts:

Brian Zhou
+86 10 57067070
Brian.zhou@carlyle.com

Tammy Li
+852 2878 5236
Tammy.li@carlyle.com

Carlyle’s Global Healthcare Network and Experience to Help Expand the Business

Hangzhou, China – Global alternative asset manager The Carlyle Group (NASDAQ: CG) today announced that it, together with Meinian Onehealth Healthcare Holdings Co., Ltd., has invested in and become the single largest shareholder of, Adicon Holding Limited, one of the largest independent clinical laboratory (ICL) companies in China. Equity for the investment came from Carlyle Asia Partners V, Carlyle’s flagship US$6.55 billion fund focused on buyout and strategic investments across a range of sectors in Asia Pacific.

Established in 2004, Adicon operates 20 fully-owned diagnostic laboratories in China, offering diagnostic testing outsourcing services to more than 10,000 active customers, including hospitals, clinics and contract research organizations (CROs) in 28 provinces. China’s ICL industry is a fast-growing market, driven by growing healthcare expenditure, rising diagnostic demand, continued technology innovation and hospital cost control trends. As an ICL industry pioneer, Adicon has developed a scalable operation with high quality standards and a network of laboratories certified with China National Accreditation Services for Conformity Assessment (CNAS). Adicon’s comprehensive test portfolio includes a range of esoteric tests, addressing diverse customer demands.

Ling Yang, Managing Director of the Carlyle Asia Buyout advisory team, said, “We are excited to have the opportunity to invest in Adicon. Adicon is a platform company, which taps into the sustained growth and innovation in China’s healthcare market and helps the health system achieve cost savings. We have seen ICL leaders grow into substantial businesses in mature markets, and believe Adicon has similar potential. We look forward to working with our partners and the existing management team to build this company together.”

The Carlyle Group has invested more than US$11.5 billion of equity in more than 65 transactions in the global healthcare industry as of June 30, 2018. In Asia, Carlyle has invested approximately US$1.5 billion in 10 healthcare companies.

As one of the first and most active international private equity investors in China, Carlyle has adopted a local approach towards investments in China for two decades. Carlyle has invested more than US$8 billion of equity in nearly 100 private equity transactions across China through its US dollar and RMB investment vehicles as of June 30, 2018.

* * * * *

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global alternative asset manager with $210 billion of assets under management across 335 investment vehicles as of June 30, 2018. Carlyle’s purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments – Corporate Private Equity, Real Assets, Global Credit and Investment Solutions – in Africa, Asia, Australia, Europe, the Middle East, North America and South America. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy, financial services, healthcare, industrial, real estate, technology & business services, telecommunications & media and transportation. The Carlyle Group employs more than 1,625 people in 31 offices across six continents.

Web: www.carlyle.com

Videos: www.youtube.com/onecarlyle

Tweets: www.twitter.com/onecarlyle

Podcasts: www.carlyle.com/about-carlyle/market-commentary

Media Contacts:

Brian Zhou
+86 10 57067070
Brian.zhou@carlyle.com

Tammy Li
+852 2878 5236
Tammy.li@carlyle.com

NASHVILLE, Tenn.–(BUSINESS WIRE)– Envision Healthcare Corporation (“Envision” or the “Company”) (NYSE: EVHC) today announced the completion of the previously announced acquisition of Envision by global investment firm KKR.

As a result of the completion of the merger, Envision has become a wholly owned subsidiary of funds affiliated with KKR, and Envision stockholders will receive an amount in cash equal to $46.00 per share of Envision common stock. As a result of the completion of the merger, shares of Envision’s common stock ceased trading on the NYSE prior to the opening of the NYSE today.

About Envision Healthcare Corporation

Envision Healthcare Corporation is a leading provider of physician-led services and post-acute care, and ambulatory surgery services. At June 30, 2018, we delivered physician services, primarily in the areas of emergency department and hospitalist services, anesthesiology services, radiology/tele-radiology services, and children’s services to more than 1,800 clinical departments in healthcare facilities in 45 states and the District of Columbia. Post-acute care is delivered through an array of clinical professionals and integrated technologies which, when combined, contribute to efficient and effective population health management strategies. The Company owns and operates 261 surgery centers and one surgical hospital in 35 states and the District of Columbia, with medical specialties ranging from gastroenterology to ophthalmology and orthopedics. In total, the Company offers a differentiated suite of clinical solutions on a national scale, creating value for health systems, payors, providers and patients. For additional information, visit www.evhc.net.

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, growth equity, energy, infrastructure, real estate and credit, with strategic manager partnerships that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.comand on Twitter @KKR_Co.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181011005441/en/

Envision Healthcare Corporation
Bob Kneeley, 303-495-1245
Vice President, Investor Relations
bob.kneeley@evhc.net
or
KKR
Kristi Huller, 212-750-8300
Cara Major, 212-750-8300
media@kkr.com

News Provided by Acquire Media

New Platform Makes First Investment in HeTian Hospital Management Co.

BEIJING–(BUSINESS WIRE)–Sep. 25, 2018– Global investment firm KKR today announced the creation of SinoCare Group (“SinoCare” or the “Company”), a hospital investment and management platform company in China. SinoCare aims to provide high-quality health care services to patients in China through the acquisition, build-out and consolidation of hospitals.

SinoCare will work alongside KKR to bring top medical resources and management experience that aim to improve service capabilities and operational efficiencies to health care service providers within the SinoCare platform, as well as to address the high demand for quality medical services in China. The Company will build its platform through organic growth and acquisitions. Additionally, KKR’s support will enable partner hospitals and care centers to be on the leading edge of health care technology and global best practices.

In conjunction with the launch of SinoCare, KKR also announced that the Company has acquired a majority stake in leading Chinese hospital management company, HeTian Hospital Management Co. (“HeTian”). The investment will support HeTian’s continued development of new medical practice areas, its expansion plans and scope to service more patients. The partnership between HeTian and SinoCare aims to serve as a model for how Chinese health care providers can be substantially enhanced through the support of a leading international investor and increased access to global best practices and medical resources.

Established by Founder and Chairman Dr. Li Fangjun, HeTian is a leading comprehensive health care provider in China. HeTian operates two general hospitals in Anhui province – Lu’An Shili Hospital and WuHe Hospital – and Lu’An HeTian Nephrosis Specialty Hospital, an operator of three dialysis centers. The group manages a total of 1,300 beds, in addition to overseeing the construction of a new hospital with 500 beds planned to be completed by 2020.

SinoCare will support HeTian’s expansion and growth through acquisitions, with a focus in third- and fourth-tier cities where medical resources are scarce and quality health care services are lacking. This is consistent with the Chinese government’s encouragement of more medical resources being extended to lower-tier cities, where there is urgent need but currently limited supply and high costs for medical treatments. There are fewer than three hospital beds per 1,000 people in China’s fourth-tier and smaller cities, according to the National Health and Family Planning Commission.

Paul Yang, Member and CEO of KKR Greater China, said, “This is a pivotal time for health care in China given the growing demand for quality medical services and treatments nationwide. We’ve seen first-hand some of the issues facing Chinese patients and are dedicated to supporting their needs through the launch of SinoCare and through the platform’s initial investment in HeTian. We are impressed with HeTian’s respected and experienced team of doctors led by Dr. Li, and believe that the company has a unique opportunity to build on its success to deliver excellent care to more Chinese patients.”

Dr. Li Fangjun, Founder and Chairman of HeTian, added, “As China faces a shortage of medical professionals and clinics, the role of private hospitals is becoming increasingly important. KKR has a long-standing reputation for bringing global best practices to its partners in the health care industry internationally, in addition to supporting Chinese entrepreneurs. We are excited to partner with SinoCare and KKR to grow our hospital group to meet the needs of patients in the Yangtze River Delta and beyond. This investment marks the beginning of an exciting and vital chapter in HeTian’s bright future.”

KKR’s investment in SinoCare is being funded from KKR Asian Fund III. Further terms of the transaction were not disclosed.

About SinoCare Group

SinoCare Group (“SinoCare”) is a hospital investment and management platform company in China created and managed by leading global investment firm, KKR. The company aims to provide high quality and accessible health care services to patients in China through the acquisition, build-out and consolidation of hospitals and introduction of global best practices.

About HeTian Hospital Management

HeTian Hospital Management Co. (“HeTian”) is a professional hospital management company specialized in operating and investing in integrated health care service providers. HeTian currently operates seven award-winning hospitals and health care centers focused on underserved Chinese cities. The company’s vision is to improve access to quality health care services by building a network of primary medical care providers supported by modern health care management best practices.

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic manager partnerships that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180925006279/en/

Source: KKR

For KKR:
KKR Asia
Cara Major, +852-3602-7335
Cara.Major@KKR.com
or
Sard Verbinnen & Co.
Rick Carew, +852-3842-2200
KKR-SVC@sardverb.com
or
KKR Americas
Kristi Huller, +1 212-750-8300
Media@KKR.com
or
For KKR China:
FTI Consulting
Dee Wang, +86 21-2315-1138
Dee.Wang@fticonsulting.com